Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
49
ONC Quote, Financials, Valuation and Earnings
Last price:
$346.22
Seasonality move
:
-3.01%
Day range:
$342.00 - $353.22
52-week range:
$196.45 - $385.22
Dividend yield:
0%
P/E ratio:
675.78x
P/S ratio:
7.85x
P/B ratio:
10.23x
Volume:
110.8K
Avg. volume:
289.7K
1-year change:
58.79%
Market cap:
$38.9B
Revenue:
$3.8B
EPS (TTM):
$0.52
Analysts' Opinion
-
Consensus RatingBeOne Medicines Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 19 Buy ratings, 0 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $406.00, BeOne Medicines Ltd. has an estimated upside of 15.58% from its current price of $351.27.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $250.00 representing 28.83% downside risk from its current price of $351.27.
Fair Value
-
According to the consensus of 20 analysts, BeOne Medicines Ltd. has 15.58% upside to fair value with a price target of $406.00 per share.
ONC vs. S&P 500
-
Over the past 5 trading days, BeOne Medicines Ltd. has underperformed the S&P 500 by -0.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
BeOne Medicines Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
BeOne Medicines Ltd. has grown year-over-year revenues for 14 quarters straight. In the most recent quarter BeOne Medicines Ltd. reported revenues of $1.4B.
Earnings Growth
-
BeOne Medicines Ltd. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter BeOne Medicines Ltd. reported earnings per share of $1.09.
Enterprise value:
36.7B
EV / Invested capital:
--
Price / LTM sales:
7.85x
EV / EBIT:
199.93x
EV / Revenue:
7.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
69.79x
Price / Operating cash flow:
74.26x
Enterprise value / EBITDA:
108.08x
Gross Profit (TTM):
$4.2B
Return On Assets:
1.1%
Net Income Margin (TTM):
1.4%
Return On Equity:
1.92%
Return On Invested Capital:
1.43%
Operating Margin:
11.55%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.2B | $3.3B | $5B | $1B | $1.4B | |
| Gross Profit | $1.8B | $2.7B | $4.2B | $780.6M | $1.2B | |
| Operating Income | -$1.3B | -$872.6M | $183.5M | -$120.3M | $163.3M | |
| EBITDA | -$1.2B | -$727.2M | $339.4M | -$49M | $200.7M | |
| Diluted EPS | -$9.27 | -$8.24 | $0.52 | -$1.15 | $1.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $4.4B | $5.7B | $4.1B | $3.9B | $5.7B | |
| Total Assets | $5.3B | $6.7B | $5.5B | $5.8B | $7.6B | |
| Current Liabilities | $1.3B | $1.4B | $1.3B | $2B | $2.4B | |
| Total Liabilities | $1.9B | $2B | $1.7B | $2.4B | $3.5B | |
| Total Equity | $3.4B | $4.7B | $3.8B | $3.4B | $4.1B | |
| Total Debt | $680.9M | $254.3M | $250.5M | $252.4M | $1.1B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.3B | -$437.4M | $786.8M | $188.4M | $403.2M | |
| Cash From Investing | $161.1M | -$517.3M | -$331.9M | -$133.9M | -$49.3M | |
| Cash From Financing | -$40.9M | $545M | $959.9M | $12.7M | $963.2M | |
| Free Cash Flow | -$1.8B | -$1B | $525.7M | $54.7M | $355.1M | |
ONC
Sector
Market Cap
$38.9B
$23.4M
Price % of 52-Week High
91.19%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-0.93%
-1.64%
1-Year Price Total Return
58.79%
-21.81%
Beta (5-Year)
0.518
0.504
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$349.73
200-day SMA
Buy
Level
$304.05
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$344.47
Relative Strength Index (RSI14)
Buy
Level
53.59
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-24.1262
50-day SMA
Buy
Level
$329.93
MACD (12, 26)
Buy
Level
6.07
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.26)
Buy
CA Score
(Annual)
Level (-0.254)
Buy
Beneish M-Score
(Annual)
Level (-2.2784)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.1457)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Stock Forecast FAQ
In the current month, ONC has received 19 Buy ratings 0 Hold ratings, and 1 Sell ratings. The ONC average analyst price target in the past 3 months is $406.00.
-
Where Will BeOne Medicines Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that BeOne Medicines Ltd. share price will rise to $406.00 per share over the next 12 months.
-
What Do Analysts Say About BeOne Medicines Ltd.?
Analysts are divided on their view about BeOne Medicines Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BeOne Medicines Ltd. is a Sell and believe this share price will drop from its current level to $250.00.
-
What Is BeOne Medicines Ltd.'s Price Target?
The price target for BeOne Medicines Ltd. over the next 1-year time period is forecast to be $406.00 according to 20 Wall Street analysts, 19 of them rate the stock a Buy, 1 rates the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ONC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for BeOne Medicines Ltd. is a Buy. 19 of 20 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ONC?
You can purchase shares of BeOne Medicines Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BeOne Medicines Ltd. shares.
-
What Is The BeOne Medicines Ltd. Share Price Today?
BeOne Medicines Ltd. was last trading at $346.22 per share. This represents the most recent stock quote for BeOne Medicines Ltd.. Yesterday, BeOne Medicines Ltd. closed at $351.27 per share.
-
How To Buy BeOne Medicines Ltd. Stock Online?
In order to purchase BeOne Medicines Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ONC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ONC
Sector
P/E ratio
675.78x
23.34x
PEG ratio
--
-0.01x
P/B ratio
10.23x
1.72x
Price / LTM sales
7.85x
1.51x
Growth Metrics
ONC
Sector
Revenue growth
41.19%
3.21%
Earnings growth
195.27%
10.12%
Revenue (5-year growth)
54.85%
6.27%
Earnings forecast
$1.30
-$0.19
Profitability
ONC
Sector
Profitability FY 2024
$3.1B
$2.7M
Return on invested capital
1.43%
-33.62%
Return on assets
1.1%
-29.68%
Return on equity
1.92%
-38.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
ONC
Sector
Total cash
$4.1B
$25M
Short term investments
--
$23.9M
Total assets
$5.9B
$72.8M
Long term debt
$1.1B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
66
DIOD alert for Feb 13
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
